PUMA Golf Releases New PROADAPT ALPHACAT Shoe
PUMA Golf has just released its new PROADAPT ALPHACAT shoe, which has been engineered to deliver the best spikeless performance imaginable and will retail at £120.
The PROADAPT ALPHACAT is the “King of Comfort” and it boasts an impressive array of innovative materials including PUMA GOLF’s proprietary ADAPT Foam, which is made from a combination of EVA Cushioning and an impact resistant polymer. The combination of the materials creates a platform that provides impact resistance, energy return, and ground feel. While the PROADAPT Multi Material Outsole, which features a high-durometer, abrasion resistant TPU perimeter that provides great stability and traction on soft surfaces while the central Crystal Rubber unit, provides exceptional ground gripping traction and a soft under foot feel on hard surfaces, giving you the confidence to hit any shot no matter the lie. The upper is an EXO Shell comprised of engendered mesh with a TPU Film that provides both structure and support as well as waterproof performance (1-year guarantee).
"The new PROADAPT ALPHACAT brings the exact energy and innovation we are about here at PUMA,” said Andrew Lawson, PLM, Footwear, PUMA Golf. “More golfers now than ever are wearing spikeless shoes, so when we approached the build of this shoe, our engineers and designers used both performance innovations and style trends to create the most advanced spikeless golf shoe PUMA has made to date. At the end of the day, the PROADAPT ALPHACAT gives golfers a shoe that they can feel confident, looking great, and perform at their best in.”
PROADAPT ALPHACAT are available in three colorways in men’s sizes 7-12. The ALPHACAT family will be available in Europe and Asia on June 15, 2021 and in North America in 2022.
The new PROADAPT ALPHACAT golf shoes are available for men: (£120 – pair), please note laced model for the women due in 2022.
For more information, visit https://pumagolf.cobragolf.co.uk/.
What do you think? leave your comments below (Comments)
comments powered by Disqus